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Abstract Since its introduction in 2003, the Shape Sig-
natures method has been successfully applied in a number
of drug design projects. Because it uses a ray-tracing
approach to directly measure molecular shape and prop-
erties (as opposed to relying on chemical structure), it
excels at scaffold hopping, and is extraordinarily easy to
use. Despite its advantages, a significant drawback of the
method has hampered its application to certain classes of
problems; namely, when the chemical structures consid-
ered are large and contain heterogeneous ring-systems, the
method produces descriptors that tend to merely measure
the overall size of the molecule, and begin to lose selective
power. To remedy this, the approach has been reformulated
to automatically decompose compounds into fragments
using ring systems as anchors, and to likewise partition the
ray-trace in accordance with the fragment assignments.
Subsequently, descriptors are generated that are fragment-
based, and query and target molecules are compared by
mapping query fragments onto target fragments in all ways
consistent with the underlying chemical connectivity. This
has proven to greatly extend the selective power of the
method, while maintaining the ease of use and scaffold-
hopping capabilities that characterized the original
implementation. In this work, we provide a full conceptual
description of the next generation Shape Signatures, and
we underline the advantages of the method by discussing
its practical applications to ligand-based virtual screening.
The new approach can also be applied in receptor-based
mode, where protein-binding sites (partitioned into sub-
sites) can be matched against the new fragment-based
Shape Signatures descriptors of library compounds.
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MEP Molecular electrostatic potential
SAS Solvent-accessible surface
AR Androgen Receptor
ARLBD Androgen Receptor Ligand Binding Domain
PCa Prostate Cancer
VS Virtual Screening
EnsD Ensemble Docking of Multiple Protein
Conformations
IFD Induced-Fit Docking
ROC Receiver Operating Characteristic
Introduction
Molecular shape remains the fundamental determinant in
our understanding of the mechanisms of bioactivity [1]. The
specificity of interactions between ligand and receptor is
largely defined by shape and electrostatic complementarity,
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with shape the most critical factor (in that a small addition
of steric bulk can dramatically increase interaction energy).
Both ligand- and receptor-based approaches to computer-
aided drug design take shape into account either implicitly,
by assuming that similar chemical structures will have
similar interactions with a target (as typified by pharma-
cophore screening methods [2, 3]), or explicitly by fitting
ligands into the volume presented by a binding site (as seen
in molecular docking [4–6]). In either case, shape is a
preeminent consideration, and given the rapid increase in
the size of available chemical libraries, it remains a chal-
lenge to efficiently screen large compound databases to
identify compounds likely to evince shape similar to a query
molecule, or to match the complementary volume of a
protein receptor.
Another argument that draws increasing attention is the
practical issue of securing intellectual property rights for
potential therapeutics. Once a concern primarily in indus-
try, this has now become a pressing consideration for
academic scientists as universities seek new sources of
funding, and see attractive possibilities in commercializing
basic research [7]. This increases the value of computa-
tional strategies that support ‘‘scaffold hopping’’, the
ability to rapidly expand the chemical space being
explored. To accomplish this, a conventional ligand-based
search strategy that relies on structure-based descriptors
must either cast a very wide net (e.g. using physicochem-
ical parameters as filters), or consider at the outset a broad
range of alternative structural classes that will likely be
suggested by chemical intuition and/or synthetic feasibility.
In the first case, most molecules collected will be false
positives, and their number will exceed the capacity of
typical secondary screens (such as molecular docking),
while in the latter case the chemical space considered will
inevitably be restricted by the initial choices made,
reducing the chances of identifying truly novel compounds.
Methods that rely on the development of structural queries
also presume a high level of chemical expertise, and may
be difficult for the non-computational specialist to apply.
Since its introduction in 2003, the Shape Signatures
method [8, 9] has proven a useful tool in a number of drug
discovery projects [10–12] (including several proprietary
investigations). The Shape Signatures technique uses a
simple implementation of ray-tracing [13], a method bor-
rowed from computer graphics imaging, to stochastically
explore the volume enclosed by the solvent-accessible
surface (SAS) of a ligand molecule, or the volume exterior
to a protein receptor site. Once generated, probability dis-
tributions are derived from the ray-trace and stored as
histograms; these are the Shape Signatures. While the ray-
tracing operation is computationally challenging, it need be
carried out only once for each library compound, and the
Shape Signatures descriptors are then rapidly compared,
with speed comparable to chemical fingerprint methods.
Moreover, a number of descriptors are generated from a
single ray-trace, which are classified as ‘‘1D’’ or ‘‘2D’’
according to the dimension of the domain of the associated
probability distribution (histogram). The single 1D
descriptor generated in the current implementation is
simply the distribution of ray-trace segment lengths, while
the 2D descriptors represent joint probability distributions
that couple shape with electrostatic potential information
sampled on the molecular surface (described in
‘‘Methods’’).
Shape Signatures present a number of attractive
advantages over other methods. First, it depends explicitly
on shape, not on the underlying chemical structure, and
thus excels at scaffold hopping; moreover, the Shape Sig-
natures descriptors have been proven to be very sensitive to
the details of molecular shape, while less so on confor-
mation, reducing the need for preprocessing of query
structures (e.g., in general, multiple conformers do not
need to be generated for a query molecule). Secondly, the
method is fast, with performance comparable to chemical
fingerprints, and offers the capability to scan a library
comprising millions of compounds in a matter of minutes.
Thirdly, the method unifies ligand- and receptor-based
approaches, since one has the option of comparing the
shapes of molecules against other molecules (shape simi-
larity), or molecules against a receptor site (shape com-
plementarity). Finally, running searches is remarkably
easy, requiring only that the end user supply a query
structure and runtime parameters to control the number of
hits returned.
Despite these advantages, Shape Signatures has suffered
from an important drawback—as one moves from query
compounds based on one or two ring systems to more
complicated and heterogeneous molecules, the selective
power of the method degrades. This is perhaps an
unavoidable side-effect of the original implementation of
the method, where all of the shape information for a
molecule is compressed into a very compact descriptor. To
illustrate, we scan the ZINC [14, 15] library with an
extended conformer of the antibiotic Novobiocin, which
comprises rings of three distinct classes (phenol, coumarin
and hexose) along with diverse substituents (Fig. 1a). The
query molecule itself (present in ZINC in multiple copies,
along with close structural analogs) does appear at the top
of the hit list (Fig. 1b), but moving down past the top ten
molecules we encounter hits that bear little resemblance to
the query, neither in the ring systems they include nor in
overall topology (Fig. 1c). While exploration of chemical
diversity is an important feature of the Shape Signatures
approach, hits that match the query only in overall size can
be more easily identified by simple property queries. While
interesting hits that feature significant similarity to the
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original query do appear in the hit list (Fig. 1d), many have
poor rank. Shape Signatures remains a useful tool (in
conjunction with other screens) when applied to complex
molecules like Novobiocin, but it becomes necessary to
retain a very large hit list, and the advantages of the method
over competing techniques become less apparent.
To remedy this deficiency, we have extensively modified
the original algorithm so that it is now fragment-based. As
described below, we retain the ray-tracing approach of the
original method, but now automatically partition molecules
into fragments based on ring systems (or by a custom
specification provided by the user). The ray-trace is like-
wise partitioned in accordance with the fragments, and the
Shape Signatures descriptors are expressed as an array of
inter- and intra-fragment contributions. When a query
molecule is compared to a database target compound, the
query fragments are mapped onto the target fragments in all
ways consistent with the underlying connectivity (including
substructure matches). Fragment-based comparison scores
are generated, which involve a weighted average of the
fragment–fragment contributions defined by the mapping,
and which are used to rank hits in order of significance. In
this way, the selective power of the method (which holds
only when well-defined shapes are represented) is carried
over to larger and more complex structures, with the added
bonus that query and target structures are mapped onto each
other in chemically meaningful ways. We stress that while
mappings must be consistent with underlying chemical
connectivity, the fragment-based Shape Signatures
descriptors are still based only on fragment shape, not
underlying chemical structure, so we expect the scaffold-
hopping capabilities of the method to be largely preserved.
In what follows we will describe in detail our new
implementation. We will discuss typical applications of the
new approach, and present a basic validation study.
Methods
Automatic fragmentation
The basis of our new approach is to fragment molecules
automatically using a simple and robust algorithm (the
method is illustrated in Fig. 2). The key idea (which is
certainly not novel) is to break molecules up based on ring
systems. The first step is to identify ring closures, which
are equal in number to the cycles in the graph of the
molecule (constructed by treating heavy atoms as vertices
and bonds as edges). Closures are located by choosing any
bond as an initial seed for a subtree, and extending the
subtree recursively to include neighboring bonded vertices,
but excluding neighbors that have already been incorpo-
rated into the tree. When the recursion terminates the
subtree is maximal [16], and any remaining bonds not
incorporated into the tree are ring closures (Fig. 2a). Ring
closures are guaranteed to be equal in number to the cycles
formed by the graph, but their positions are not uniquely
determined and depend upon the specific path of execution
taken by the algorithm.
Next, paths of bonds are generated recursively, using
ring closures as initiation points, and with paths extended
using all contiguous non-closure bonds. The union of all
paths that end at the closure initiation point define a single
ring system (Fig. 2b). As shown in the diagram, a fused
ring system will include multiple ring closures, and these
are eliminated from further consideration once incorpo-
rated into the union of paths associated with any other
closure in the same ring system. Once all ring closures
have been processed in this way, the molecule is parti-
tioned into an initial collection of identified ring systems,
along with the remaining non-ring components (at this
stage only heavy atoms have been considered).
Connected components of the heavy-atom graph are next
identified, and these belong to one of the following categories:
(a) a ring system, (b) a fragment neighboring two or more ring
systems, or (c) a fragment neighboring a single ring system.
Components that border two or more ring systems are always
assigned as separate fragments; components that border a
single ring system are assigned as separate fragments if they
contain more than five heavy atoms, and are subsumed into the
neighboring ring system if smaller. Finally, hydrogens are
assigned to the fragments they are attached to.
As an alternative to the automatic procedure just
described, it is also possible for the user to supply a file that
assigns atoms (by index) to numbered fragments. This is
useful in cases where some criteria other than ring system
membership is preferred for defining fragments (e.g. when
considering peptides or other polymers), and is a pre-
requisite if the fragment-based approach is to be applied to
exterior ray-traces for receptors. In receptor-based model-
ing, ‘‘fragments’’ correspond to sub-sites of the binding
site, and we assume these must be defined by the end user.
While the symmetric handling of ligands and receptors is
an attractive feature of Shape Signatures, here we will
discuss only the ligand-based application of the method.
Surface generation
The shape of a molecule in Shape Signatures is described
by its SAS, which is generated using the inward face of a
rolling probe (representing a single solvent molecule), as
originally described by Lee and Richards [17] and later
implemented in widely-used algorithms by Connolly [18].
In this work, an updated version of the SMART algorithm
[19] is applied, which generates a triangulated surface that
closely matches the ideal mathematical form of the SAS.






Fig. 1 a Extended
conformation of Novobiocin.
A Shape Signature descriptor
was prepared from this structure
and used as query against the
ZINC database. b Top hits for
Novobiocin. All of these are
structurally identical to the
query, although reflecting minor
changes in conformation (e.g.
changes in conformation of
hexose ring with respect to the
query). c Novobiocin hits
21–26. These are roughly
similar in size to the query, but
lack significant shape matches
involving ring systems or
substituents. d Compounds
ranked much lower in the hit the
list, which do exhibit interesting
substructural similarity to the
query. These molecules all
feature a hexose moiety and a
coumarin derivative, while
including terminal substituents
or linkers that deviate from the
query. The rank positions range
from 183 (ZINC43682806) to
6,118 (ZINC26723060)
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Although the updated algorithm includes a new approach
to dealing with potentially self-intersecting surface, for the
purposes of Shape Signatures this modification is unim-
portant and should not significantly influence results. Fig-
ure 3 shows a triangulated surface for Novobiocin generated
using the updated SMART tool. Atomic coordinates for
SMART are taken directly from database entries if available;
if the structure format does not define explicit coordinates,
these are first generated using CORINA (http://www.mole
cular-networks.com).
Ray-tracing
The ray-tracing algorithm is similar to that of the original
Shape Signatures code [8], but has been re-implemented
and updated to take into account partitioning of molecules
into fragments. Briefly, a rectangular grid of specified
spacing is first overlaid on the triangulated surface of the
molecule, and surface elements are assigned to cubes of
this acceleration grid [20] based on contact with the ele-
ment corners—if any corner of an element lies within the
boundaries of a grid cube, then the element is assigned to
that cube. Thus an element can be assigned to a minimum
of one cube, but to no more than three. Surface elements
are also assigned to atoms, and the number of assigned
atoms depends on the class of molecular surface (contact,
saddle of reentrant) the element belongs to [18]. (Briefly,
elements of contact surface are assigned to one atom,
saddle elements to two, and reentrant elements to three
atoms.) Moreover, each element is assigned to a single
principal atom, namely the one closest to the geometric
center of the element.
The ray-trace is initiated at a randomly chosen element
that forms part of the contact surface of the molecule.
Contact surface is found where the solvent probe slides
with two degrees of freedom (locating a fully solvent-
exposed portion of an atom), and this class of surface is
unlikely to involve any feature (e.g. a narrow invagination)
that might inhibit the initial propagation of the ray. The ray
is started at the center of the element, and perpendicular to
the element plane. For ligand-based applications the goal is
to explore the geometry defined by the interior of the
surface, and the ray is initially propagated antiparallel to





Fig. 2 a Input structure. One bond (highlighted in red) is selected at
random as the initial seed. b Paths (curved black) are launched from
one end of the seed bond and propagated recursively. A path is
terminated if continuation would mean contacting an existing portion
of the same path. The terminating bonds discovered by the paths are
identified as ring closures (heavy black). c Paths are launched
recursively from the ends of the ring closures; unions of non-self-
intersecting paths that connect one end of the ring closure to the other
identify ring-based fragments. d After ring based fragments (colored
red and blue) are defined, remaining connected components of the
molecule define terminal or internal non-ring fragments (green)
Fig. 3 Triangulated surface for Novobiocin generated by Smooth
Molecular Surface Triangulator (SMART). Top: Starting structure,
with fragment assignment indicated by color coding. Bottom:
Triangulated surface. The surface elements are color-coded using
the Connolly/Richards convention of assigning contact (blue), saddle
(yellow) and reentrant (red) surface categories
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hand, when characterizing the shape of a protein receptor
site the ray is initially directed in the same direction as the
surface normal vector, so the ray-trace inhabits the volume
exterior to the molecular surface. When performing a
receptor-based ray-trace, the initial element is chosen at
random from contact elements belonging to atoms of the
binding site, which is defined by the user.
Once started, the ray propagates by the rules of optical
reflection. (The polygonal triangulated molecule can be
imagined as a sort of distorted mirrored disco ball for the
purpose of visualization.) Progress of the ray is tracked
through the cubes of the acceleration grid, and each cube
encountered is checked for associated surface elements; if
the cube is nonempty, each surface element it contains is
tested to see if it supports a reflection, and the computed
reflection points are ordered by position along the ray. The
reflection point closest to the previous reflection point (or
the initiation point, if at the start of the trace) terminates the
current ray-trace segment, and defines the start of the next
segment (Fig. 4). The direction of the new segment is
determined by the angle of incidence at the reflecting
element, plus a random perturbation that is uniformly
distributed within a cone centered on the ray direction that
corresponds to ideal reflection. The angle of the cone is a
user-supplied parameter (typically chosen as 5 or less),
and this random perturbation serves to prevent the ray from
ever becoming ‘‘stuck’’ for a long period between opposing
surface elements with antiparallel normals.
If an exterior ray-trace is being performed for a protein
receptor site, the ray-trace is restricted to those atoms in the
user-defined site (which is specified by supplying a text file
containing the site-atom indices). This is accomplished by
simply truncating the trace if it encounters a non-site sur-
face element, and reinitiating at a randomly-chosen posi-
tion within the site; the ray-trace segments leading up to
the escape of the ray are retained. Similarly, in the rare case
that normal propagation of the ray-trace fails (sometimes
observed if a ray exactly intersects the boundary between
two elements), then the ray-trace is simply truncated at the
last successful reflection, and the algorithm is restarted.
In addition to the position of each reflection, we also
retain the molecular electrostatic potential (MEP) (which is
interpolated from the values pre-computed at the vertices
of the incident surface element, using imported partial
atomic charges). MEP values are used in the construction
of ‘‘2D’’ Shape Signatures, as described in the next section.
Each segment of the ray-trace is associated with up to
two atoms, and we presume these have been assigned to
numbered molecular fragments. A ray-trace segment is
categorized as intra- or inter-fragment depending upon
whether the two atoms belong to the same or different
fragments, and the fragment identities of each segment are
retained for later analysis.
Shape Signatures descriptors
The Shape Signatures descriptors are histograms that
accumulate selected probabilities derived from the ray-
trace. ‘‘1D’’ signatures correspond to probability distribu-
tion with one-dimensional domain, while ‘‘2D’’ descriptors
are joint probability distributions with two-dimensional
domain. (Signatures with higher dimension are possible,
but have not been actively investigated yet.) Figure 5
summarizes the signatures currently implemented.
The simplest 1D descriptor is the distribution of ray-
trace segment lengths, which is easily computed from the
ray-trace reflection positions given a histogram bin width;
the bin-width parameter is user-supplied, but must match
the value used to construct target databases, and is thus not
freely selectable. The first 2D signature currently supported
corresponds to the joint probability distribution that
describes the sum of the segment lengths incident at a
given reflection point, together with the MEP computed at
the reflection point (Fig. 5d). Two variants of this basic
signature type are also computed: a reduced 2D descriptor,
which includes only two bins for the electrostatic potential,
corresponding to positive or negative sign, and a reduced
inverted descriptor (not shown), again with two electro-
static bins but with the sign of the potential reversed. The
motivation for the reduced descriptors is our recognition
that it is overly restrictive to require identical MEP dis-
tributions over the surfaces of two molecules in order to
Fig. 4 Geometry of ray-tracing. a Cubes of the acceleration grid that
the propagating ray passes through are shaded in this 2D illustration.
Each cube may be associated with surface elements, and the elements
attached to any cubes touched by the ray are checked for possible
intersection with the ray. The first intersection detected along the path
of a ray locates the next reflection. b The direction of the reflected ray
is defined by the vector normal to the surface (n), with the normal,
incident and reflecting rays all lying in the same plane, and with equal
angles between the normal vector and the incoming and reflected rays
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deem them similar; having the same sign of the potential is
adequate to suggest a useful match. The inverted 2D
descriptor is to support receptor-based applications, where
one is interested in identifying small molecules that are
complementary in shape and electrostatic potential to a
target; by generating a descriptor with the sign of the
potential inverted ‘‘up front’’, it is easier to use the same
scoring machinery (described below) to evaluate comple-
mentary electrostatic matches.
In accumulating the descriptor probability distributions,
we take into account the fragment identification of the ray-
trace segments, and maintain separate histograms for intra-
and inter-fragment contributions (illustrated in Fig. 6). This
is readily achieved, as each reflection is supported by a
surface element, which in turn is associated with a primary
atom, which is in turn a member of a fragment. Ray-trace
segments with reflections in the same fragment contribute
to an intra-fragment histogram; segments with reflection
points in distinct fragments contribute to an inter-fragment
histogram. The original, ‘‘global’’ histogram for all seg-
ments can be recovered by summing corresponding bins for





Fig. 5 Computational flow to
generate Shape Signatures
descriptors. a Input molecular
structure. b Assignment of
atomic radii, generation of
solvent-accessible surface using
rolling probe (heavy outline).
c Ray trace; two successive
segments are show, involving a
reflection at position r. The
incoming segment has length
4 A˚, the segment leaving the
reflection has length 5 A˚. The
molecular electrostatic potential
(MEP) at position r (computed
from atomic partial charges) is





by a histogram. The ‘‘2D’’
descriptors accumulate the joint
probability of observing a sum
of segment lengths centered at a
reflection, coupled with the
MEP measured at the reflection
point. For the 2D-MEP
descriptor the numerical value
of the MEP is used directly to
identify a histogram bin, for the
‘‘reduced’’ descriptor only the
sign of the potential is taken
into account
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global histogram when scoring reproduces the original
Shape Signatures approach, while the intra-fragment his-
tograms serve as descriptors for the individual fragments
that comprise the molecule. While the inter-fragment his-
tograms represent a significant fraction of the ray-trace
segments (typically about 20 %), and undoubtedly capture
important aspects of molecular shape, we do not consider
them at present when comparing molecules. They are
nonetheless retained along with the intra-fragment
descriptors and are available for use in improved scoring
methods yet to be developed.
Scoring
We retain the basic scoring approach of the original Shape
Signatures method, and apply a discretized version of the








here hql is the height of query histogram q at bin l, and it is
assumed that l varies over corresponding bins (height, and
also MEP in the case of 2D histograms). If the histograms
are normalized (the case here), then S(q,t) is expressed in
units of probability. The minimum score possible is zero,
corresponding to identical histograms, and the maximum is
2, the case for two distributions with no common support.
We now extend this approach to handle fragment-based





in the query molecule to fragments f ta
 
in
the target (where the subscripts range over the available
fragment indices in each molecule). Mappings must be
consistent with the underlying chemical connectivity, in
the sense that if query molecule fragments x and y are




y maps to f
t
m ,
then this implies that fragments l and m are bonded in the
target molecule. Also, it is not required that all fragments
in query and target be covered by the mapping (i.e. sub-
structure matches are supported). The mapping algorithm
we employ starts with the set of all possible mappings
between single fragments in query and target, and recur-
sively expands these in all ways consistent with fragment
connectivity, and with duplicates detected and removed.
The mapping expansion is ‘‘greedy’’ in that mappings are
Fig. 6 Generation of fragmented Shape Signature descriptor histo-
grams. Here ray-trace segments are color-coded using the same
scheme as the molecular fragments. A segment whose end-points lie
in the same fragment contributes to the appropriate intra-fragment
histogram, while a segment with reflections in two distinct fragments
contributes to the corresponding inter-fragment histogram
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retained only after maximal extension (e.g. the initial single
mappings between individual fragments are not retained).
Figure 7 illustrates the possible mappings between two
small molecules comprising multiple fragments.
Fragment-based scoring involves a straightforward
extension of Eq. 1

























In Eq. 2, the sum is over all fragment–fragment links m
in mapping M, from query molecule q to target t. Each
query fragment f
q
xðmÞ of mapping element m contains c
q
xðmÞ
intra-fragment ray-trace segments, similarly there are ctlðmÞ
segments associated with corresponding target fragment
f tlðmÞ. The existing scoring function S() is applied to each
pair of mapped fragments, and the resulting total score is
simply the sum of these contributions, weighted by the
number of ray-trace segments associated with the
fragments being compared.
A single comparison between two molecules will in
general produce a number of mappings, the specific num-
ber determined by both the number of fragments in query
and target molecules, and their topology. The ‘‘hits’’ are
ranked in order of ascending score (again, low scores
indicate greater similarity), and a hit record also retains the
details of the mapping between query and target, and the
percentages of ray-trace segments unused in query and
target. The latter numbers correlate with the volumes of the
fragments excluded when forming the match, and these can
be used in downstream filtering to remove substructure
matches that involve too few atoms to be interesting.
Generating descriptors for the ZINC database
Shape Signatures comparisons are rapid (even though
fragment-based scoring is inevitably slower than the ori-
ginal approach). In contrast the ray-tracing operation is
time-consuming even with grid acceleration in place,
requiring on the order of 1 s CPU time for each molecule.
That said, the computation of Shape Signatures is a one-
time investment for a given target database, suggesting the
most efficient approach is to gain short-term access to a
massive computing resource to carry out descriptor gen-
eration for the database, after which more modest com-
puting facilities will suffice to carry out searches.
In recent years, ‘‘cloud computing’’ has been recognized
as an attractive solution in those situations where compu-
tational requirements can change dramatically in a short
time frame [21] (e.g. in electronic commerce applications
where customer demand can fluctuate dramatically as a
function of the season or even time of day). In a cloud
computing environment, data centers provide access to
virtual machines that are distributed across the hardware in
their facilities, and which can run a variety of operating
systems; in addition, there will typically be available a
distributed storage system which uses data redundancy to
Fig. 7 Possible mappings
between a query with three
fragments and a target
compound with four. The text
corresponding to the illustrated
mapping is highlighted. Since
our fragment mapping
algorithm is greedy, not all of
the mappings suggested here
would be retained; for example,
the ‘‘seed’’ mapping (1–2)
would be expanded to
((1–2),(2–3))
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reduce access time and ensure reliability and fault toler-
ance. Perhaps the most successful and widely-used cloud
computing environment is Amazon Web Services (AWS)
which includes both a distributed storage service (‘‘Simple
Storage Service’’, or S3) and an environment for config-
uring and deploying virtual machines (‘‘Elastic Compute
Cloud’’, or EC2).
We have used AWS to generate Shape Signatures
descriptors for version 11 of the ZINC database [14, 15].
ZINC is a library that comprises the major public
resources (PubChem [22], NCI [23]) along with the cat-
alogs of the major chemical vendors (e.g. SigmaAldrich
(http://www.sigmaaldrich.com), Maybridge (http://www.
maybridge.com)) and smaller specialty suppliers. ZINC
covers a very large chemical space, includes many drug-
like molecules, and generally features compounds likely
to be readily acquired; thus it is an ideal resource for
identifying compounds as early leads against a biological
target of interest. While intellectual property rights would
be limited if a ZINC compound were introduced
unmodified as a therapeutic agent, active compounds
identified in ZINC can serve as a testing ground for
structure–activity hypotheses, and provide the starting
point for synthetic strategies aimed at developing truly
novel molecules.
Our calculations were carried out using custom Python
scripts along with Boto (https://github.com/boto/boto,
http://boto.readthedocs.org) an object-oriented Python
toolkit which facilitates easy access to the S3 and EC2
features of AWS. We began by manually configuring a
single Linux machine instance with requisite libraries,
scripts and command-line tools. This machine instance was
archived, and we could then deploy as many instances of
the machine as needed. The ZINC database was down-
loaded as individual component libraries, and each of these
in turn divided into multiple multi-mol2 files (http://www.
tripos.com/data/support/mol2.pdf), each containing about
20,000 molecules. To reduce cost, we allocated machines
using ‘‘spot requests’’, where a price per hour of CPU
activity is offered by the user (and must be accepted by
AWS) before each machine is started. While this generally
ensures a cost-effective usage rate, there is the risk that the
machine will be prematurely terminated if demand rises
and the adjusted minimum price exceeds the initially-
accepted offer. To mitigate the possible loss of calcula-
tions, we subdivided each multi-mol2 file into 10 smaller
units of about 2,000 molecules, and furthermore grouped
each collection of 10 units into five pairs; a pair (com-
prising *4,000 molecules) was submitted to a single two-
core virtual machine for processing, and this required about
3–4 h of wall-clock time. For the initial calculations a spot-
request price of $0.10/machine-hr was always adequate,
but with increasing demand the threshold had to be raised
to $0.15/machine-hr for calculations to run. There were
occasional lapses in service, and a number of calculations
failed due to timeouts when attempting to access input
data, which was stored in S3. It was critical to carefully
review the output for missing results, and to reschedule
failed computations.
The output descriptors were computed using a custom
command-line program written in objective-C, an object-
oriented extension of the C language (devel-
oper.apple.com). The Linux implementation relies heavily
on the GNU port of the NextStep Foundation classes
(http://www.gnustep.org) to support complex data struc-
tures and for access to machinery for archiving, and for
access to operating system resources. The Shape Signature
descriptors were saved in a custom compressed XML
format, and the results generated by each virtual machine
were archived, compressed and transferred for storage to
S3.
The Shape Signatures descriptors generated on EC2
virtual machines and stored in S3 were finally transferred
to a single server (artemisdiscovery.com) and imported as
binary objects into a MySQL (www.mysql.com) database.
The use of a relational database allows for rapid random-
access retrieval of signatures, enables easy duplicate
checking (critical for us, since the compound memberships
of the component ZINC libraries significantly intersect),
and provides an easy route to attaching new descriptor
information (such as logP) in the future. The database
schema is simple, consisting of the one-to-one Shape Sig-
natures table that indexes each descriptor by ZINC com-
pound code and numerical index.
Fast prefiltering
Individual Shape Signature comparisons are fast, requiring
about 100 ls to complete. However, with the introduction
of the fragment-based approach, the comparison of two
molecules may involve dozens of mappings, depending on
the number of fragments and their topology. For the sim-
plest (yet very common case) of linear arrangements of
fragments in both query and target, the number of map-
pings M(q,t) is easy to compute:











Here, m and n are the number of fragments in query and
target respectively; the first term is the number of mappings
that link single fragments, the second term counts
mappings involving 2 or more links k between query and
target, with the assumption that mapped groups of
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fragments are contiguous. (The factor of 2 in Eq. 4
accounts for the fact that mappings involving two or
more links have two possible orientations.) A comparison
of two molecules that each comprises five fragments then
implies 85 mappings. While we have not accumulated
statistics of fragment counts in ZINC, it is clear that the
introduction of fragment comparisons will increase search
times by an order of magnitude or more.
Fortunately, it is easy to efficiently prefilter the
database by quickly identifying a lower bound on the
fragment-based distance between two compounds. We
begin by extracting from the full Shape Signatures
descriptor for a library molecule the 1D (shape-only)
components for the fragments, along with the segment
counts for these, and storing the information in a com-
pact binary format. (Fragment connectivity information is
ignored.) Binary databases of these reduced descriptors
are assembled for the compounds in each library, and
these databases are small enough to be maintained as
shared memory resources on our server. A shared
resource is accessible to any running process, and read-
ing data from a memory resource is very fast (since no
disk access is involved). The binary shared resource for
a target library is created at the same time that the
corresponding Shape Signatures descriptors are imported
to the local MySQL database.
When comparing a query against a reduced target
descriptor, the best score for each query fragment is found
using any available fragment in the target, irrespective of
fragment connectivity (which is ignored when prefiltering),
and with no limit on the number of times a target fragment
can be used. A weighted sum of the optimal fragment–
fragment scores is assembled, using the same approach
implemented for full fragment-based scoring (Eq. 2). The
prefilter score thus presents a lower bound for the score of a
maximal match between query and target. The fast prefilter
is used to generate an initial hit list of 20-30,000 com-
pounds, which are then subject to detailed comparison by
the full mapping algorithm. It is the full mapped matches
which are presented to the user.
While the prefilter could potentially screen out some
useful matches (since substructure matches can evince a
better score than mappings involving all fragments), this is
mitigated by retaining a large prefilter list (5–10 X the final
number of hits to be retained). We also emphasize that our
mapping strategy is ‘‘greedy’’ by default, with maximal
expansion of each seed single-fragment mapping, and that
substructure matches are thus deemphasized.
While the CPU time for a query depends critically on
the structure and search parameters, a typical Shape Sig-
natures search against ZINC for a drug-like molecule takes
about 15 min of CPU time for a 2.8 GHz Intel server
running the OS X operating system.
Characteristics of fragment-based scoring
As noted above, the hit list for Novobiocin generated using
the original non-fragment Shape Signatures method inclu-
ded many ZINC compounds that are interesting matches to
the query, involving variations of its structure while
retaining overall form; however, these often appear with
poor rank, and are distributed at random among the hits.
Table 1 compares the ranks of the compounds in Fig. 1
as found using the original, non-fragment approach and our
new method (chemical structures are shown in SM-1). The
IDs of compounds judged interesting (as evincing signifi-
cant structural similarity to the query) are highlighted in
bold. Clearly, the fragment approach has succeeded for this
subset in demoting uninteresting compounds (in fact, all
but one fall out of the top 5,000 hits), and promoting
interesting hits that were previously low-ranked to a high
position. At the same time, the hit compounds that are
essentially identical to the query remain at the top of the
list, albeit with some reordering of rank position. A
detailed examination of top hits reveals a clear enrichment
in compounds that we deem interesting on the basis of
chemical intuition (i.e. evincing variation with respect to
the query while retaining significant overall similarity).
The apparent randomness of rank order using the ori-
ginal non-fragment approach is illuminated by examining
Table 1 Comparisons of compound hit ranks






















(*) not ranked in top 5,000 hits
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the distribution of scores. For this purpose it is useful to
apply a log transform to the distance scores, as these are
compressed in a narrow range (0–2)—at the same time we
recast this as a similarity measure, with increasing positive
score representing smaller distance between descriptors:
TðsÞ ¼ 1  log2ðsÞ ð5Þ
The transformed score T(s) has a lower bound of zero
(corresponding to a maximal inter-descriptor distance of 2.),
and tends to positive infinity as the raw score approaches
zero. (Since the generation of Shape Signatures involves a
stochastic process (ray-tracing), the raw (distance) score for
a comparison will usually not be identical to zero even if the
chemical structures and atomic coordinates for query and
target match exactly.) Figure 8 compares transformed score
distributions for Novobiocin used as a query against ZINC,
for both the original and fragment-based approaches. In the
absence of fragment scoring, the distribution is sharply-
peaked, suggesting that compounds have been screened on
the basis of rough size similarity with little selectivity as to
the details of shape; in contrast, the introduction of
fragment-based scoring dramatically broadens the
distribution, and a sampling of structures from various
portions of the distribution confirms that selectivity is
greatly enhanced. Structures selected from the top tail of the
distribution evince close similarity to the query (similar to
the examples in Fig. 1d), those taken from the middle
typically represent rough substructure matches, while
compounds selected from the low end generally represent
poor matches between diverse fused ring systems (which are
treated as single fragments).
Validation study
Our approach to formulating an extensive validation for
fragment-based Shape Signatures focuses mainly on it’s
ability to select structurally diverse compounds likely to
Fig. 8 Comparison of
transformed score distributions
(Eq. 5) for non-fragment (a) and
fragment-based b Shape
Signatures. In (b) some
fragment matches typical of
poorer scores are illustrated,
with the query (Novobiocin) on
the left, the matching ZINC
compound on the right; these
typically involve partial
matches between query and
target compound
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exhibit a desired bioactivity; paradoxically, a rigorous
validation based on shape comparison alone is a secondary
consideration. This is because a key feature of our
approach is the ability to make good substructure matches,
where the selected library compounds may evince signifi-
cant local shape dissimilarity with respect to the query, and
where a straightforward determination of hit quality
becomes problematic if we focus only on global shape
similarity. That said, we have also carried out a validation
study using an independent shape comparison technique, as
described below.
Thus, we mainly focused on showing the ability of
Shape Signatures to select a list of hit molecules with
significant enrichment in a desired biological activity. We
focus on the Androgen Receptor (AR), an important drug
target in Prostate Cancer (PCa) therapy [24], and one with
which we have significant prior computational experience
[25]. This is a target with a number of representative
crystal structures available, including complexes with a
variety of ligands. Moreover, the ZINC database
(zinc.docking.org) includes a large selection of annotated
binders for this target, and the Directory of Useful Decoys
[26, 27] (DUD, dud.docking.org) provides a pool of non-
binding drug-like molecules with strong physicochemical
similarity to known AR actives, serving as a source of
negative controls.
We carried out three validation studies, described below,
each involving a different Virtual Screening (VS) scenario.
The first is primarily directed toward establishing bench-
marks to evaluate the quality of Shape Signatures Hits by
applying a secondary validation screen, here molecular
docking using a rigid receptor. The second study expands
on the first by considering a much larger population of
compounds, while the third study explores the impact of
taking receptor flexibility into account. Finally, we carried
out a fourth study to directly assess the capability of the
method in screening compounds purely on the basis of
shape, by comparing against an independent state-of-the-
art shape comparison tool.
Computational details
Protein structure preparation and alignment
High-resolution (\1.80 A˚) crystal structures of Androgen
Receptor Ligand Binding Domain (ARLBD) used in the
validation study (Table 2) were all downloaded from the
RCSB Protein Data Bank [28] (http://www.rcsb.org) in
Table 2 Ligands used as Shape Signature queries for VS of ZINC database




1Z95 198 R-BICATULAMIDE 1.80
2AM9 TES TESTOSTERONE 1.64
2AX6 HFT HYDROXYFLUTAMIDE 1.50
Crystal structures of human Androgen Receptor Ligand Binding Domain (ARLBD) used as queries for Shape Signatures Screening of the ZINC
database for AR binders. Entries are listed in alphabetic order along with relative PDB identifiers, ligand identifiers, chemical structures, ligand
names and resolution (A˚)
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September 2012. Structures were prepared using the Pro-
tein Preparation Wizard [29, 30] available from Schro¨-
dinger [31] (Suite 2012 for OS X). During preparation,
protein receptors were aligned on the three-dimensional
(3D) coordinates of PDB ID 2AM9 [32] as reference
template; missing hydrogen atoms were added and mole-
cules of water located within 5 A˚ of the ligand were
retained. The program Prime [33–35] was used to predict
missing side chains, when necessary. As for the ligands,
bond orders and formal charges were adjusted before per-
forming full Molecular Mechanics (MM) minimizations
(by OPLS [36–38] 2005 force field, at 0.30 A˚ convergence)
of AR complexes by running the impref utility from the
Impact program [39].
Ligand preparation
All ligands submitted to docking simulations of Case
Studies I to III were either extracted from the ZINC data-
base or downloaded from the DUD in mol2 format and
prepared using the LigPrep [40] tool from Schro¨dinger.
Chemical structures were submitted to generation of ster-
eoisomers and alternative ring conformations. The tool
Epik [41–43] was used to produce different ionization and
tautomeric states at physiological pH. Finally, energy
minimizations of all structures were performed with the
OPLS 2005 force field.
Physicochemical property filters
The ‘‘Filter’’ ligands protocol available through the Virtual
Screening Workflow [44] was used to select chemical
structures resulting from Shape Signature screening of the
ZINC database (Hits) or the full set of Decoys downloaded
from the DUD web-site. We used the QikProp [45] tool to
estimate physicochemical properties of chemical structures
before filtering by the Lipinski’s Rule-of-5 [46] (log P \ 5;
kDa \ 5; HB donors B 5; HB acceptors B 10) and
excluding scaffolds containing poor drug-like properties or
reactive chemical moieties.
Molecular docking
Different crystal structures of ARLBD co-crystallized with
a ligand were used as docking receptors, particularly: PDB
IDs 2AM9 for Single Conformation Rigid-Receptor
Docking (Case Studies I and II); PDB IDs 2AM9, 1XOW
[47], 1Z95 [48] and 2AX6 [49] for Ensemble Docking of
Multiple Protein Conformations (EnsD) [50] (Case Study
III).
Docking areas for each receptor conformation (docking
grids) were defined by choosing the default size of the
enclosing box and by excluding co-crystallized ligands
from the binding pockets. Simulations were all performed
using Glide [51–54] with Extra-Precision (XP) Scoring
Function (SF), allowing full ligands flexibility and
accounting for Epik state penalties for re-scoring. XP-
descriptors were generated. The OPLS 2005 force field was
used to perform post-docking energy minimizations.
Hierarchical clustering and similarity screen
Hierarchical clustering and similarity screen were per-
formed of both the AR Ligands and the Fragment Based
Shape Signatures Hits using Canvas [31, 55]. Radial fin-
gerprints (ECFP) were selected as binary descriptors [56].
Structure similarity was calculated using the Tanimoto
coefficient. In hierarchical clustering, the linkage was
performed using the ‘‘average method’’. In similarity
screen, the AR Ligand ZINC03814409 was used as com-
mon reference molecule to evince structural similarity.
(Since ZINC03814409 was not included in the original top
80 VS hits, it was added to this set before the calculation.)
Phase Shape screening
Phase Shape screening was performed using the program
Phase [57, 58]. Descriptors were generated applying the
pure volume scoring (‘‘Shape Sim Pure’’) and compared to
1D Shape Signatures. Ligands were extracted from the
ZINC database or downloaded from the DUD. Existing
conformers were kept and additional conformers were
generated (up to 100). Multiple conformers (up to 10) per
rotatable bond were retained. During conformational
searches, amide bonds were allowed to freely rotate.
Case Study I: Comparison of Shape Signatures Hits
to AR Ligands, Decoys and ZINC drug-like compounds
by rigid receptor docking
Here we tested Fragment-Based Shape Signatures for their
ability to provide screening hits that are likely to be tight
binders to the ARLBD, by virtue of shape similarity to
known AR ligands (i.e. compounds that co-crystallize with
ARLBD). Specifically, we obtained docking scores of
Shape Signatures Hits by rigid receptor docking against a
single AR conformation, and compared these to results for
positive and negative control compounds. We are espe-
cially interested in the enrichment of molecules with ‘‘good
to excellent docking scores’’ among the Shape Signatures
compounds.
Virtual screening by Shape Signatures
We performed iterative screening of the ZINC database
using a set of four structurally different ligands used as
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query molecules (Table 2) in Shape Signatures searches
(Fig. 9).
It is well known that the selection of query molecules is
a critical aspect in ligand-based VS, particularly in the case
of ligands producing significant induced-fit effects in a
receptor upon binding. Recent efforts have been expended
to analyze, classify and retrieve sets of ‘‘diverse’’ binding
sites for the same protein when accommodating structur-
ally different chemical classes of binders, based on auto-
matic clustering of volume overlaps [59].
In a recent work [25], we have performed accurate
structural analysis of a number of crystal structures of the
human ARLBD in complex with a diverse set of ligands,
which revealed insights into AR flexibility upon binding to
structurally distinct compounds. Our results suggested
similarities and differences in the molecular determinants
responsible for AR binding, and were used as the founda-
tions for selecting appropriate ligands for Shape Signatures
searches. All queries were extracted from publicly avail-
able, high quality crystal structures of the human ARLBD
(resolution \ 1.80 A˚; Table 2): 2AM9, 1XOW, 1Z95 and
2AX6. To account for the structural diversity of AR
binders, we selected two Steroid (SL; 2AM9 and 1XOW)
and two Non-Steroid Ligands (NSL; 1Z95 and 2AX6).
Both NSLs behave as AR antagonists of the wild-type AR,
while exerting agonistic properties against mutant ARs.
All co-crystal structures were downloaded from RCSB
Protein Data Bank in September 2012 and prepared
following the standard workflow implemented in the Pro-
tein Preparation Wizard. Ligands were extracted from their
respective receptors and saved in a Shape Signatures
compatible format (mol2). For each query (4 known AR
binders), 1D Shape Signature descriptors (shape only) were
used to individually search all ZINC compounds by com-
parisons with their previously generated Shape Signatures
descriptors. (Details in ‘‘Methods’’.)
Hits were excluded from the final lists if more than 25 %
of query or target were unused when forming a mapped
comparison (see ‘‘Methods’’). For each run, a total of
20,000 ZINC molecules were pre-filtered, and from these
up to 5,000 compounds were selected by detailed mapped
comparison to form the final hit list for each query. The
union of the four hit lists provided a total of 15,338 com-
pounds (including duplicates), which were merged to pro-
duce a non-redundant list of 14,032 molecules.
Benchmark compound sets
As a metric for assessing the performance of VS by Shape
Signatures, we estimated ligand enrichment of top-ranking
screening hits (assessed by detailed molecular docking)
versus three sets of reference control compounds, thus
comparing docking score distributions for a total of four
benchmark sets (Table 3):
(1) Shape Signatures Hits (‘‘test set’’), comprising 80
compounds selected from the four Shape Signature
searches (top 20 for each query ligand).
(2) AR Ligands including all 79 annotated AR binders
(‘‘true positives’’) downloaded from the DUD.
(3) AR Decoys Subset, consisting of 80 compounds
randomly selected from the full set of AR Decoys
(2,854 compounds) downloaded from the DUD. By
definition, AR Decoys show physicochemical prop-
erties similar to those of AR ligands but with
dissimilar topologies. Therefore, they are unlikely to
be binders.
(4) ZINC Random Selection from the ‘‘Drug like’’ Subset,
including 80 unique compounds that were down-
loaded by choosing the ‘‘Clean Drug-like subset’’
(query performed in September 2012), then browsing
for sample molecules. A total of 136 compounds were
downloaded, 80 of which were randomly picked. All
these compounds show physicochemical properties
according to Lipinski’s Rule-of-5 and, according to
their selection process, they are improbable AR
binders.
When comparing against the test set of Shape Signature
Hits, we defined AR Ligands as positive controls, while AR
Decoys and the ZINC Random Selection Set were assigned
as negative controls.
Fig. 9 Virtual screening (VS) of the ZINC database (v. 11, *11
millions of chemical structures). VS was performed using a two-step
procedure: (1) Ligand-based screening by Shape Signatures; (2)
Receptor-based confirmation of top-scoring hits (*20 %) by molec-
ular docking simulations upon filtering by physicochemical properties
according to Lipinski Rule-of-5. Typically, a minimum of 1 % of
reconfirmed hits with high drug design potential is prioritized for
purchase (or synthesis) upon visual inspection of binding modes and/
or approval by expert medicinal chemists before in vitro testing. Both
new analogs of existing lead compounds or novel chemical scaffolds
are likely to be obtained
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Molecular docking
Benchmark compounds were prepared for docking simu-
lations according to the ligands preparation procedure
using LigPrep. Total numbers of structures obtained after
preparation are reported in Table 3. Docking simulations
were performed against the crystal structure of the human
ARLBD (PDB ID 2AM9) as rigid receptor, using Glide
with XP SF. (Refer to ‘‘Computational Details’’ in the
‘‘Methods’’ section.)
Post-docking processing was conducted using the
‘‘Select Top Poses’’ script, available from Schro¨dinger
[31]. For each compound, best binding modes were
selected according to docking score (kcal/mol).
The final step is to evaluate the likelihood of having
identified a true positive from the docking score, which
requires establishing thresholds. Defining such thresholds
for docking scores can be a non-trivial task, since the
significance of scores depends critically on the target pro-
tein. In our case, the main criterion to define hit signifi-
cance was the docking scores distribution of the known AR
Ligands (Fig. 10). A secondary consideration was the
accepted definitions of significant score ranges as described
in the literature for Glide [52–54] XP SF. These two
principles were in fact in good agreement, and led to the
following docking score (s) definitions:
• s B -9 kcal/mol: excellent docking score, hits have
high chances of being true AR binders.
• s B -7 kcal/mol: about 20 % of AR Ligands have
approximately this docking score (as shown in
‘‘Results’’), which was set as a putative threshold to
define virtual screening hits, and possible true positives.
(A score of -6.5 kcal/mol is the value below which fall
98.6 % of best binding modes of AR Ligands when
docked against multiple receptors; however, to limit the
false positive rate, we chose a more stringent cutoff of
-7 kcal/mol.)
• -6 \ s \ - 6.5 kcal/mol: generally regarded as poor
scores, where SFs have lost their ability to clearly
distinguish between true positives and false negatives.
In fact, few or no AR true Ligands lie in this score
range (3.8 % in Case Study I and 0 % in Case Study III;
discussed in ‘‘Results’’), which was named ‘‘the grey
zone’’, since no conclusions can be readily drawn;
• s C - 6 kcal/mol: low chances of being true positives
in the design of AR binders.
Case Study II: Virtual screening by Shape Signatures,
reconfirmation by rigid receptor docking
and comparison to Decoys Set
Using the scoring thresholds developed and successfully
applied for a relatively small set of positive and negative
controls (Case Study I), our next step was to expand our
scope and assess the performance of Shape Signatures in
the context of a larger set of negative controls, here the
entire set of AR Decoys available at DUD.
Virtual screening by Shape Signatures of the ZINC
database was performed as described in the corresponding
section of Case Study I, however for the present case an
expanded selection of top hits was used to match the
increased size of the negative control set.
Benchmark compound sets
We estimated ligand enrichment of top-ranking Shape
Signature Hits versus the entire set of AR Decoys available
at the DUD. Our sets for benchmark calculations include
(Table 4):
1. Shape Signatures Hits, comprising 2,854 ZINC com-
pounds selected by choosing top-ranking hits from the
merged Shape Signature searches.
2. AR Decoys, including the full set of 2,854 structures
showing physicochemical properties similar to those of
AR Ligands but with dissimilar topologies. Therefore,
they are unlikely to be binders.
All chemical structures were prepared following the
Ligands Preparation procedure (described in the ‘‘Com-
putational Details’’ of the ‘‘Methods’’ section) to provide
final lists of 25,532 and 11,793 individual structures in case
(1) and (2), respectively (Table 4).
It should be noted that although the number of hits
selected in this study for validation by molecular docking










# ZINC IDs 80 79 80 80
# Docked structures 664 478 253 237
# Best poses 75 67 74 35
Best score
(kcal/mol)
-10.7 -11.0 -9.90 -7.95
Worst score
(kcal/mol)
-4.24 -5.66 -3.05 -0.730
For each benchmark set used in Validation Case Study I (Sh-Sig Hits:
Shape Signatures Hits; AR Ligands & Decoys: from the Directory of
Useful Decoys DUD; ZINC Sel: Random Selection from the ‘‘Drug
like’’ Subset), the number of ZINC compounds selected for validation
by molecular docking simulations are reported (# ZINC IDs), along
with the actual numbers of structures obtained by Ligands Preparation
(# Docked Structures). As for docking results, the number of ZINC
IDs with at least one binding mode (# Best poses) is reported along
with docking score ranges by Glide XP Scoring Function
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was established for consistency with AR Decoys (2,854
each set), it represents about 20 % of the total compounds
(non-redundant list) retrieved by Shape Signatures
(14,032), which is a reasonable fraction of compounds to
choose for computational reconfirmation in a real-world
virtual screening campaign. In fact, Case Study II follows
our expected workflow for Shape Signatures, with this
ligand-based method used as a primary screen, and with a
significant fraction of the top-ranking compounds validated
by a second, more computation-intensive approach, such as
detailed molecular docking (Fig. 9).
Before submitting these ligands to molecular docking
simulations, their drug-likeness was assessed by applying
molecular filters to discard molecules that do not comply
with Lipinski’s Rule-of-5 or contain reactive chemical
moieties. To do so, we used the ‘‘Filter’’ ligands protocol
available through the Virtual Screening Workflow
(Schro¨dinger Suite 2012) to calculate their physicochemi-
cal properties by QikProp and remove reactive chemical
structures. Thus, only final sets of ‘‘drug-like’’ compounds
(22,880 hit and 10,848 decoy structures) were submitted to
docking simulations (Table 4).
Molecular docking
Molecular docking simulations of both Shape Signatures
Hits and AR Decoys were performed against a single AR
conformation, as described in the corresponding section of
Case Study I, and in the Computational Details of the
Methods section.
Case Study III: Comparison of Shape Signatures Hits
to AR Ligands and ZINC drug-like compounds
by protein ensemble docking
The first two case studies seek to establish Shape Signa-
tures as an effective tool in virtual screening, by providing
a fast first filter of very large compound collections and
Fig. 10 Case Study I Results. Frequency distributions of Glide XP
docking scores (kcal/mol) for benchmark set compounds obtained by
Rigid-Receptor Docking of Single Protein Conformation: a Shape
Signature Hits (80 starting compounds, 75 individual binding modes);
b annotated AR Ligands available at DUD (79 starting compounds,
67 individual binding modes); c random-selected subset of AR
Decoys available at DUD (80 docked compounds, 74 individual
binding modes) and d subset of ZINC Drug-like compounds random
selected from the ‘‘clean compounds library’’ (80 starting compounds,
35 individual binding modes obtained). Two docking score thresholds
are indicated: score (s) B 7 kcal/mol, suggesting hits (but not leads,
in which case more stringent criteria should be satisfied) as possibly
true positive, on condition that further validation are capable of
confirming; s B 9 kcal/mol, excellent score, meaning hits having
high chances of being true AR binders
Table 4 Case II Study Statistics: Shape Signatures screening and
rigid receptor docking
ShSig. Hits AR Decoys
# ZINC IDs 2,854 2,854
# Structures prepared 25,532 11,793
# Docked structures 22,880 10,848
# Best poses 2,101 2,373
Best score (kcal/mol) -10.8 -10.9
Worst score (kcal/mol) 1.85 0.771
a For each benchmark set used in Validation Case Study II (Sh-Sig
Hits: Shape Signatures Hits; AR Decoys: from the Directory of Useful
Decoys DUD), the number of ZINC compounds selected for valida-
tion by molecular docking simulations are reported (# ZINC IDs),
along with the actual numbers of structures obtained by Ligands
Preparation (# Structures Prepared), filtering by physicochemical
properties and elimination of unwanted moieties, like reactive sub-
structures (# Docked Structures). As for docking results, the number
of ZINC IDs with at least one binding mode (# Best poses) is reported
along with docking score ranges by Glide XP Scoring Function. AR
Decoys were downloaded from the Directory of Useful Decoys DUD
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producing hits with desired shapes that, upon confirmation,
are likely to develop into lead candidates for a particular
drug target (AR in our case).
While Shape Signatures, the first step of our virtual
screening implementation, is ligand-based, the second is
receptor-based, namely by molecular docking. In keeping
with common practice, we made our validation step as
efficient as possible by docking against a single, rigid
model of the target receptor. However, it is well known that
ARLBD adopts significantly different conformations upon
binding to various chemical classes of ligands, suggesting
that the false negative rate in our first studies might be
exaggerated (as alternative conformations of the receptor
were ignored), leading to an underestimation of the
enrichment factor attainable with the Shape Signatures
approach.
To incorporate AR plasticity into a flexible receptor
docking protocol, we performed Ensemble Docking of
Multiple Protein Conformations (EnsD) [50]. This protocol
involves individually docking Shape Signature hits and
representative reference-set compounds against all the
available forms of the receptor (here the four ARLBD
conformations co-crystallized with the ligands used as
screening queries), followed by selection of top scoring
docking poses (by absolute docking score, kcal/mol) as
best binding modes.
Benchmark compound sets
Benchmark set compounds are listed in Table 5 and
include: Shape Signature Hits (80 total), AR Ligands (79
total) and ZINC Random Selection from the ‘‘Drug like’’
Subset (80 total), that were collected as described in the
proper section of Case Study I.
Molecular docking simulations
Molecular docking simulations of benchmark set com-
pounds were individually performed against an ensemble
of multiple protein structures, selected to reproduce
induced-fit effects of ARLBD upon binding to ligands used
as Shape Signatures queries. Thus, crystal structures of
2AM9, 1XOW, 1Z95 and 2AX6 were prepared according
to the Protein Preparation Wizard before using the Glide
tool to generate docking grids and perform molecular
docking simulations at XP level SF. (Described in ‘‘Com-
putational details’’ paragraph of the ‘‘Methods’’ section.)
Then, for each compound set, docking results against
individual protein structures were processed using the
‘‘Select Top Poses’’ script, available from Schro¨dinger
platform. For each compound within a set, the best binding
mode against a particular receptor was selected as relative
best pose according to the lowest docking score (kcal/mol).
Comparisons of up to four relative best poses, obtained for
each compound of a particular set against multiple protein
conformations, allowed selecting the lowest docking scores
(kcal/mol) as absolute best poses.
Case Study IV: Comparison with an independent shape
screening method
Rescoring fragment based shape Signatures Hits by Phase
Shape
Since it is not practical for us to generate Phase Shape
descriptors for the [11 million compounds in our aug-
mented ZINC database, we opted for ‘‘re-scoring’’ hits
generated by Fragment Based Shape Signatures to enable a
direct comparison of the two methodologies.
To this end, we considered hits retrieved by searching the
ZINC database using Novobiocin as query ligand. This query
compound choice was motivated to ensure a high order of
complexity in the ‘‘compound fragmentation’’ stage required
during the Shape Signatures generation. As a matter of fact,
Novobiocin represents a challenging example of multiple
fragment mappings, as shown in Fig. 3.
We used as an additional target for comparison the ‘ad hoc’
collection comprised of 79 AR Ligands and 2,854 AR Decoys
from the DUD, plus 80 random selected compounds from the
ZINC database (total of 3,013 individual structures), as
introduced above. This set includes a number of steroidal
compounds, and against this set we used Testosterone (ligand
from PDB complex 2AM9) as the query. Testosterone pre-
sents a single fragment in our new Shape Signatures approach,
and will lead to results in line with the original non-fragment-
based implementation. This permits a comparison of efficacy
of the original and new approaches for enriching compound
selections solely on the basis of shape.
Table 5 Case study III statistics: Shape Signatures screening and
ensemble docking
Shsig. Hits AR Ligands ZINC Sel.
# ZINC IDs 80 79 80
# Docked structures 664 (9 4) 478 (9 4) 237 (9 4)
# (Absolute) best poses 78 70 68
Best score (kcal/mol) -10.7 -11.2 8.30
Worst score (kcal/mol) -4.91 -5.66 -0.495
For each benchmark set used in Validation Case Study III (Sh-Sig
Hits: Shape Signatures Hits; AR Ligands: from the Directory of
Useful Decoys DUD; ZINC Sel: ZINC Random Selection from the
‘‘Drug like’’ Subset), the number of ZINC compounds selected for
validation by molecular docking simulations are reported (# ZINC
IDs), along with the actual numbers of structures obtained by Ligands
Preparation that were submitted to docking against 4 receptors (#
Docked Structures; 9 4). As for docking results, the number of ZINC
IDs with at least one binding mode (# (Absolute) best poses) is
reported along with docking score ranges by Glide XP Scoring
Function




We tested the ability of fragment-based Shape Signatures
to provide virtual screening hits with high potential to
identify chemical classes of AR binders. To reconfirm
Shape Signatures results, we calculated hit rates (number of
hits within a particular range of docking score) by per-
forming molecular docking simulations against a single AR
conformation (PDB ID 2AM9). We used docking scores
(kcal/mol) as a measure of ligand enrichment of com-
pounds from the test set (top scoring Shape Signatures
Hits) against positive- (AR Ligands) negative-control
compounds (AR Decoys and ZINC Drug-like Subset).
Ideally, docking scores of the test set should be clearly
better (more negative docking scores or higher numbers of
good scoring hits) than those obtained from any of the
negative controls. In addition, it would be very desirable to
obtain hit rates of compounds retrieved by Shape Signa-
tures searches that are ‘‘closer’’ to the positive control than
any negative controls. (Important to mention that all the
compounds in the AR Ligands set are experimentally
proven AR binders, while VS hits are typically not
expected to be true positives after experimental
verification.)
Distributions of Glide XP docking scores (kcal/mol) of
Shape Signatures Hits, AR Ligands (positive control),
Decoys and ZINC Drug-Like Subsets (negative controls)
are listed in Table 6 by counting the total number of
compounds according to scoring category, using the scor-
ing ranges defined in ‘‘Methods’’. Histograms (by Canvas
Schro¨dinger) [55] showing frequency distributions of
benchmark set compounds within Glide XP score ranges
(kcal/mol) are reported in Fig. 10a–d.
The results met these expectations, with Shape Signa-
tures Hits evincing a behavior much closer to true AR
Ligands (positive controls) than either AR Decoys or
Table 6 Case Study I Results: Shape Signatures screening and rigid receptor docking
Score (kcal/mol) Sh-Sig. Hits AR Ligands AR Decoys ZINC Sel.
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Docking score distributions (Glide, XP) of benchmark set compounds (Sh-Sig Hits: Shape Signatures Hits; AR Ligands & Decoys: from the
Directory of Useful Decoys DUD: ZINC Sel: ZINC Random Selection from the ‘‘Drug like’’ Subset) are given as percentages of compounds that
meet the criteria and as absolute numbers (in parenthesis). For each set, percentages are given (1) as the number of compounds having a score
above or below a particular threshold over the total number of compounds submitted to docking simulations and (2) over the total number of
compounds with at least one binding mode retrieved by individual docking runs. Percentages and absolute numbers of compounds without any
binding modes predicted are also reported (no binding modes)
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randomly-selected drug-like ZINC compounds (negative
controls). There is strong preference for Shape Signature
Hits over negative controls, as reflected in higher per-
centages of compounds, in both the ‘good’ and ‘excellent’
docking score ranges (s B -7 to s B -9 kcal/mol).
Furthermore, clear separations appear among frequency
distributions of docking score (kcal/mol; Glide XP) of
Shape Signature Hits compared against negative control
sets (Fig. 10), thus confirming our hypothesis that Shape
Signatures performs well in filtering large compound col-
lections for molecules having desired shape similarity to a
bioactive query, and therefore likely to constitute true
positive hits against a drug target of interest.
Case study II
With a view of identifying an expanded set of chemical
compounds that might serve as AR modulators, we put in
place a VS workflow based on a two-step procedure
(Fig. 9): first, we performed Shape Signature screening of
the ZINC database with multiple active compounds selec-
ted as searching queries; second, we reconfirmed top-
ranking hits by molecular docking, but in this case with the
entire AR decoy set, thus providing a more realistic
screening scenario. This second study is supported by the
results of Case Study I, which confirmed our choice of
docking scoring ranges as measures of hit significance.
We used four distinct Shape Signature queries (Table 2)
to screen version 11 of the ZINC database, which consisted
of 11,080,665 compounds. A total number of 14,032 Shape
Signatures hits were obtained by merging results from
individual screening campaigns, selecting *0.13 % of the
initial library for computational follow-up. Of these, we
selected 2,854 top-ranking hits (*20 %) that were sub-
mitted to reconfirmation by molecular docking. In the
interest of docking accuracy we chose Glide XP SF and we
saved overall computational time by using a rigid receptor
protocol with a single AR conformation.
Overall, virtual screening by Shape Signatures produced
remarkably high hit rates. As previously discussed, we
considered a docking score -9 kcal/mol as a reliable
threshold to select compounds having strong predicted
binding (in the range of low micromolar to nanomolar IC50
values). We calculated hit rates (%) of Shape Signatures
screening (Table 7) in two ways: as the total number of hits
with a particular docking score, in this case s B -9 kcal/
mol (135 compounds), (1) over the total number of struc-
tures obtaining at least one binding mode by docking
simulations (2,101), that is 6.4 %, and (2) over the total
number of Shape Signatures Hits (2,854) initially selected
for docking calculations, i.e. 4.7 %. (Hit rates obtained at
additional score values are reported in Table 7.)
As for the comparison between Hits and Decoys it was not
surprising that in significantly increasing the number of top-
ranking hits submitted for reconfirmation by docking (from
*0.6 % or 80/14,032 in Case Study I to 20 % or 2,854/
14,032 in Case Study II) that we observed slightly lower
fractions of compounds with good to excellent docking
scores (Table 6 versus Table 7). This was not unexpected,
since we included a much larger proportion of compounds
whose Shape Signatures were less similar to those of the
active query molecules. Nevertheless, the distribution of
Shape Signatures hits clearly outperforms that obtained by
the tested Decoys (Table 7), by always reporting higher
numbers of compounds in the desired docking score ranges
(s B -7 kcal/mol and s B -9 kcal/mol) as well as having
Table 7 Case Study II Results: Shape Signatures screening and rigid
receptor docking
Score (kcal/mol) Sh-Sig. hits AR decoys
















































Docking score distributions (Glide, XP) of benchmark set compounds
(Sh-Sig Hits: Shape Signatures Hits; AR Decoys: from the Directory
of Useful Decoys DUD) are given as percentages of compounds that
meet the criteria and as absolute numbers (in parenthesis). For each
set, percentages are given as the number of compounds having a score
above or below a particular threshold over (1) the total number of
compounds submitted to docking simulations and (2) over the total
number of compounds with at least one binding mode retrieved by
individual docking runs. Percentages and absolute numbers of com-
pounds without any binding modes predicted are also reported (No
Binding Modes)
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significantly lower numbers of compounds that populate less
desirable score values (s [ -7 kcal/mol).
In addition, with access to data for a much larger popu-
lation of molecules, we were able to generate Receiver
Operating Characteristic (ROC) curves for Shape Signatures
Hits (Fig. 11). The raw data for the plots was generated by a
custom Python script which computed true- and false-posi-
tive rates, using the Shape Signatures score as the variable
threshold parameter to demarcate predicted actives from
inactives in the hit list, and with a fixed Glide docking score
used as a the benchmark to label compounds as positive or
negative. The ROC curves, which visually confirm the per-
formance of Shape Signatures as a binary classifier, are rel-
atively insensitive to choice of docking score benchmark,
provided the threshold is within 1 kcal/mol of our existing
standard of -9 kcal/mol.
Interestingly, we conclude by observing that trends in
the hit-rates (Table 7) agree with those obtained in Case
Study I (Table 6), and this is a good indication that Shape
Signatures performances estimated for the small com-
pound-sets in Case Study I (*80 compounds each) are,
with a close approximation, confirmed and can be easily
applied to a larger set of screening compounds.
Case study III
Protein flexibility is a critical aspect of molecular recog-
nition, and conformational changes that occur upon binding
are responsible for induced fit effects that are crucial in
improving receptor/ligand affinity [60]. In a previous study
[25], to deal with ARLBD plasticity, we developed a
flexible receptor docking protocol based on induced fit
docking [61–64] (IFD by Schro¨dinger, Suite 2010 on Linux
Platform) to successfully reproduce geometries of com-
plexes of known ligands and to predicting binding modes
for novel compounds. We have demonstrated that IFD
succeeds in ‘‘blind ligand docking’’, where no structural
data is available and only chemical activities of compounds
against the drug target of interest are known. Here, how-
ever, our main goal is not to explore new receptor con-
formations adopted upon binding, but to evaluate
molecules with shapes supposed to be complementary to a
particular drug target by docking them into their matching
protein structures. Thus, we performed Ensemble Docking
(EnsD) of investigated molecules against the collection of
all AR structures from which the four ligands, used as
Shape Signature queries, were previously extracted.
EnsD results for the benchmark set-compounds,
including Shape Signature Hits, AR Ligands and ZINC
Drug-like Set, are reported in Table 8 and Fig. 12 (by
Canvas). We find that EnsD outperforms the prediction of
binding modes generated against single ARLBD, espe-
cially in the cases of Shape Signature Hits and, to a lesser
degree, AR Ligands (Table 8 versus Table 6 and Fig. 12
versus Fig. 10). This is not surprising, as four dissimilar
ligands, each representing a structurally distinct target,
were used as queries against ZINC. By providing all of the
target structures as potential binding partners, we more
fully explore the range of available docking modes, albeit
at greater computational expense.
Comparison between frequency distributions of docking
scores (by Canvas) for Shape Signatures Hits and AR
Fig. 11 Case Study II Results.
ROC curves for Shape
Signatures Hits obtained by VS
of the ZINC database for AR
antagonists are obtained by
setting progressive thresholds in
the Shape Signatures score used
to demarcate ‘‘predicted’’
positives from negatives, and
with a fixed docking score
benchmark used to label ‘‘true’’
positives and negatives.
Molecular docking simulations
were performed by single
receptor conformation of
ARLBD
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Ligands (Table 8; Fig. 12a, b, respectively) show a striking
similarity: in both cases the majority of compounds fall
below the -7 kcal/mol threshold, while comparable frac-
tions of chemical structures score below the -9 kcal/mol,
suggesting excellent binding affinity. In contrast, docking
score distributions of compounds in the ZINC Drug-like
Subset (Table 8; Fig. 12c) show a totally different profile,
with nearly all chemicals scoring above the -7 kcal/mol
threshold, and neither of them being better than -8.3 kcal/
mol (for comparison, best scoring AR Ligands and Shape
Signature Hits are -11.2 kcal/mol and -10.7 kcal/mol,
respectively).
Analysis of top scoring Fragment Based Shape
Signatures Hits
The primary goal of this work was to establish Fragment
Based Shape Signatures as a powerful approach in VS,
particularly suitable in scaffold hopping. In this regard, we
provide a description of the ‘‘top 80’’ screening hits, as
representative results of the entire VS campaign.
We primarily focus on describing the general features of
relevant scaffolds retrieved, likewise on identifying spe-
cific patterns of substituents, regardless of the chemical
moiety they decorate. In particular, we seek to determine
whether Fragment Based Shape Signatures is able to ‘‘fish
out’’ compounds simultaneously exhibiting shape similar-
ity and chemical diversity.
‘‘Shape similarity’’ by hierarchical clustering
We performed ‘‘hierarchical clustering’’ of the top 80
Fragment Based Shape Signatures Hits (description in the
‘‘Computational Details’’ section), which grouped in 17
clusters of different size, the largest comprising 34 mole-
cules (cluster 17). A dendrogram of the hierarchical clas-
sification is shown in Fig. 13. The plot is color-coded by
docking score (by EnsD), ranging from good (-10.7 kcal/
mol; in blue) to bad (-4.91 kcal/mol; in red) predicted
binding.
Steroid scaffold
Not unexpectedly, our screening picked a significant
number of structures containing the steroid scaffold
(Fig. 13, bordeaux box). Although they all shared a com-
mon core, many of them introduced non-obvious variations
in positions, such as C-3 on ring A and/or C-17 on ring D,
known to bear the molecular determinants responsible for
AR binding. These structures populated clusters 5–6,
10–12, and 15.
An important aspect in VS is the ability of the screening
approach to succeed in scaffold replacement. Thus, we
shifted our attention on hits bearing chemical moieties
other than the parent steroid core.
Diterpene scaffold
One chemical class of interest was represented by hits
containing the diterpene scaffold, which populated clusters
1 and 2 (blue box). Interestingly, all diterpene derivatives
identified by VS showed consistent docking modes with
scores up to -10.7 kcal/mol, indicating strong predicted
binding.
In support of these findings, a number of natural pro-
ducts belonging to this chemical class have recently gained






AR Ligands ZINC Sel.
































0 % 15.0 % (12/80)
17.6 % (12/68)






s C (-5.0) 1.25 % (1/80)
1.28 % (1/78)
0 % 27.5 % (22/80)
32.4 % (22/68)
s C (-4.0) 0 % 0 % 11.3 % (9/80)
13.2 % (9/68)
s C (-3.0) 0 % 0 % 8.75 % (7/80)
10.3 % (7/68)










Docking score distributions (Glide, XP) of benchmark set compounds
(Sh-Sig Hits: Shape Signatures Hits; AR Ligands: from the Directory
of Useful Decoys DUD: ZINC Sel: ZINC Random Selection from the
‘‘Drug like’’ Subset) are given as percentages of compounds that meet
the criteria and as absolute numbers (in parenthesis). For each set,
percentages are given as the number of compounds having a score
above or below a particular threshold over (1) the total number of
compounds submitted to docking simulations and (2) over the total
number of compounds with at least one binding mode retrieved by
individual docking runs. Percentages and absolute numbers of com-
pounds without any binding modes predicted are also reported (no
binding modes)
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popularity for their ability to modulate the AR, and for
their potential use as chemotherapeutic agents in the
treatment of PCa. To cite a few examples, the dietary
diterpene compound carnosol was found to serve as AR
antagonist, and to inhibit the growth of PCa cells as well as
to reduce tumor formation (by 36 %) in Xenograft mice
[65]. In addition, a number of diterpene derivatives isolated
from Cryptomeria japonica were shown to inhibit AR in
PCa cells [66]. One of them, the abietane diterpene HDHS
was reported to also suppress tumor growth in vivo through
antiproliferation and proapoptosis [67].
Phenanthrene scaffold
Another interesting case, derivatives of the phenanthrene
ring (green box), decorated with a variety of different
substituents, represented a very recurrent chemical moiety
in the ‘‘top 80’’ hit list (clusters 3, 7, 8, 9, 13, 14). Many of
these structures reported a good predicted binding (up to
-8.20 kcal/mol). Encouraged by these results, we searched
the list of 2,854 Fragment Based Shape Signatures hits and
we found a number of additional derivatives of the phen-
anthrene ring, some evincing very good docking scores.
We point out that some phenanthrene derivatives are
known to serve as AR binders, and we (again) took two
examples from the literature in support of our findings. First,
the phenentren-yl derivative ZINC03814427 (connected
gray box) is one of the compounds enclosed in the AR Ligand
set from the DUD (our positive control). Second, we found in
the current version of the ZINC database (version 12) the
phenantrenone derivative ZINC13473932 (not included in
version 11 used in the screening), proposed by researchers at
Pfizer as a member of a novel chemical class of
glucocorticoid receptor antagonists with moderate binding
affinity for human AR [68].
Although our VS did not place the specific compounds
cited from the literature at the very top of the hit lists, their
active scaffold was retrieved as a high-ranking chemical
moiety, providing a strong indication as to the remarkable
scaffold hopping ability of Fragment Based Shape Signa-
tures. This is especially meaningful considering that mol-
ecules belonging to this class were fished out in the top 80
hits from screening multiple times the entire ZINC data-
base (11 millions of compounds).
Common substituents
Another example revealing the intrinsic ability of our method
for scaffold replacement is represented by the hits constituting
cluster 16. Strikingly tolerant to structural diversity, this
cluster grouped 5 small ‘‘fragment-like’’ molecules, all
showing different scaffolds (orange box). As for the substi-
tutions, three of them shared the exact same groups decorating
their principal chemical moieties, while two additional com-
pounds shared only one structural feature. One molecule in
particular showed a docking score of -6.72 kcal/mol, which
is very promising given its small size.
High diversity cluster
Highly populated, cluster 17 represents a collection of
diverse structures (34 total), the majority of which are
closed analogs of the non-steroidal drugs Hydroxyfluta-
mide or Bicatulamide (Table 2). Additional structures
presenting a range of variations over the scaffold rings,
while maintaining the overall linear backbone of the parent
Fig. 12 Case Study III Results. Frequency distributions of Glide XP
docking scores (kcal/mol) for benchmark set compounds obtained by
Ensemble Docking of Multiple Protein Conformations: a Shape
Signature Hits (80 starting compounds, 78 individual binding modes);
b annotated AR Ligands available at DUD (79 starting compounds,
70 individual binding modes) and c subset of ZINC Drug-like
compounds random selected from the ‘‘clean compounds library’’ (80
starting compounds, 68 individual binding modes obtained). Two
docking score thresholds are indicated: score (s) B 7 kcal/mol,
suggesting hits (but not leads, in which case more stringent criteria
should be satisfied) as possibly true positive, on condition that further
validation are capable of confirming; s B 9 kcal/mol, excellent score,
meaning hits having high chances of being true AR binders
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molecules, were also found. A successful substructure
replacement is evinced by the VS hits ZINC00897408,
which is indeed the Bicatulamide drug, and the closed
analog ZINC65734823 (bicatulamide sulfoxide) bearing
the –SO2– to –S– substitution (fuchsia box). Interestingly,
the latter substitution is well tolerated in that position [69],
and indeed it is found in the AR Ligands ZINC0384375
and ZINC03814372 from the DUD set (connected gray
box).
‘‘Chemical diversity’’ by similarity screen
One challenge in shape-based screening is to collect
structures evincing a certain degree of structural diversity
with respect to query molecules, usually natural ligands.
Thus we used the natural AR agonist Testosterone
(ZINC03814409) as the parent structure, and we performed
a Similarity Screen of two compound sets, the top 80 VS
hits and the AR Ligands.
Fig. 13 Hierarchical Clustering of Hits collected by Fragment Based
Shape Signatures. Clustering by ECFP, coloring by docking score
(kcal/mol). As reference compounds, known AR binders are marked
with (asterisk) and included in gray boxes connected to the respective
clusters. Boxes containing structures are colored according to cluster
numbers
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Overall, our analyses (Fig. 14) revealed a much lower
degree of similarity to the parent steroid (by ECFP fin-
gerprints) shared by Shape Signatures Hits (0.02 B Tan-
imoto Similarity B 0.14) than by the AR Ligands
(0.02 B Tanimoto Similarity B 0.29). Clearly, this was an
indirect indication that, on equal number of molecules,
Fragment Based Shape Signatures introduced a higher
degree of chemical diversity from the parent steroid than
observed in known AR binders.
Collectively, these data demonstrate the ability of Shape
Signatures to produce screening hits enriched in
compounds with high drug discovery potential, and point to
the utility of our method as in virtual screening and drug
design.
Case study IV
In our final study, we analyzed the utility of fragment-
based Shape Signatures scores to predict similarity purely
on the basis of shape (as opposed to likely bioactivity). To
this end, we used the Schro¨dinger Phase tool, which can
directly compare molecular shape using a volume overlap
Fig. 14 Similarity Screen. Testosterone (ZINC03814409) served as the parent structure in a similarity screen of a the top 80 VS hits, and b the
AR Ligands
Fig. 15 Case Study IV Results.
ROC curves generated for
Shape Signatures in comparison
with Phase Shape. Curves were
obtained for re-scoring
Novobiocin hits (a) and (b) and
for screening the ad hoc
collection by Testosterone as
query ligand (c) and (d). In both
cases, two thresholds of Phase
Shape score were set. As an
example, in (a) the legend
(48 ?/860 -) means 48
positives, 860 negatives with
phase threshold = 0.6
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approach. Two query/target sets were used, Novobiocin
versus the top 1,000 Shape Signatures hits found for this
query in our implementation of the ZINC 11 database, and
Testosterone vs. our ‘ad hoc’ collection of AR ligands and
decoys described above. We visualized the results using ROC
curves to compare true-positive and false-positive rates, with
the Shape Signature score used as the variable control
parameter. In each case, the Phase comparison was the
benchmark of shape similarity, with a fixed Phase score
threshold employed to assign shape similarity or dissimilarity.
We discovered that the decomposition of the target sets
into positives and negatives (shape similar or dissimilar to
the query) was very sensitive to the choice of Phase score
threshold. Taking a suggested threshold of 0.65 from the
literature as a starting point [70], we bracketed this value
with thresholds of 0.6 and 0.7. As shown in Fig. 15, the
ROC curves reveal good performance for fragment-based
Shape Signatures in identifying true positives, especially
with the more restrictive Phase threshold of 0.7. Interest-
ingly, the multi-fragment Novobiocin query (Fig. 15a, b)
shows better performance than the single-fragment Tes-
tosterone query (Fig. 15c, d). Since the Testosterone
comparison effectively mimics the previous non-fragment
Shape Signatures algorithm, this provides evidence that the
new fragment-based method can offer significantly-
improved sensitivity and selectivity.
Conclusions
In this work, we describe the fragment-based implementa-
tion of Shape Signatures, and demonstrate that it is a pow-
erful tool for computer-aided drug design [8–12].
Essentially, we prove that the new methodology outperforms
the older version by dramatically enhancing its selective
power, while retaining all the advantages offered by the
original implementation. Furthermore, we report a number
of case studies used to fully assess the performance of Fag-
ment-Based Shape Signatures as a tool in practical VS.
We conclude by summarizing three important features
that emerge from these studies, which highlight Fragment-
based Shape Signatures as a unique, as well as innovative
methodology for computational chemistry and drug design.
First, Shape Signatures is a fast and effective way of
screening very large compound collections. We have
demonstrated that the method can produce hit lists highly
enriched in interesting molecules likely to be active against
a selected target. Second, Shape Signatures is very user-
friendly approach, accessible to chemists at every level of
computing expertise, and not requiring formulation of
complex queries or construction of pharmacophores. One
advantage of filtering databases by Shape Signatures is to
assist and facilitate the process of visual inspection and
application of chemical intuition by expert medicinal
chemists (typically not computational specialists) by
allowing them to focus on a significantly reduced number
of high quality hits, which at the same time feature sig-
nificant chemical diversity. Third, and very importantly,
Shape Signatures does not explicitly involve chemical
structure and this makes it an ideal tool allowing scaffold
hopping and identification of novel chemical classes of
drug targets modulators.
The Shape Signatures approach is available on our ser-
ver (artemisdiscovery.com), and accounts will be provided
for academic use at no cost, upon request.
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